We thank Somdat Mahabir for his insightful comments and the clarification of a number of points related to our work. 1 We agree that biomarkers should have been used for the assessment of body magnesium status. However, biomarkers of magnesium are not routinely collected in large-scale epidemiological studies. For example, cellular magnesium is suggested as the preferable marker of magnesium status, 2 but it is rarely used in large epidemiological studies due to budget constraints. Serum magnesium, though suggested to respond to dietary manipulation, 3 is narrowly controlled in a state of homeostasis and may not represent the body's magnesium status very well. 4, 5 Although the bioavailability and measurement error are inevitable limitations, dietary and supplemental magnesium intakes are widely used in epidemiological studies to rank participants and calculate the relative risk.
We have included C-reactive protein (CRP) assessment methods in Table 1 in the original article 1 under the heading 'Outcome assessment.' In most of the original studies, body mass index and race/ethnicity were adjusted in the models. This information is also documented in Table 1 in the original article 1 under the heading 'Adjusted variables'. We agree that the health status of participants may affect the CRP levels. However, the original studies have adjusted for many health conditions, including diabetes, heart disease, hypertension and other related variables. Presumably, findings from the original studies are not substantially biased. Certainly, the results of primary studies may be confounded by other unknown or unmeasured health endpoints. Of note, our study is a meta-analysis, in which we were not able to adjust for the highlighted potential confounding variables. Besides, our ability to conduct sensitivity and/or stratified analyses was limited by the lack of information in the primary studies. Nevertheless, we concur with and appreciate Somdat Mahabir's suggestions for future studies.
